Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.75 |
| ▸ | CNR2 | P34972 | 3/20 | 0.75 |
| ▸ | CNR1 | P21554 | 2/20 | 0.75 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.75 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.75 |
| ▸ | INHA | P05111 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | HTR2A | P28223 | 1/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.75 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.75 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.75 |
| ▸ | TRPV2 | Q9Y5S1 | 1/20 | 0.75 |
| ▸ | TRPM7 | Q96QT4 | 1/20 | 0.56 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21365936 | 0.91 | PPARG (0.61) | PPARGCNR2CNR1TRPV1SLC6A3 | |
| Cannabigerol SCHEMBL144819 | 0.86 | PPARG (1.00) | PPARGCNR2CNR1TRPV1SLC6A3 | |
| Cannabigerol SCHEMBL12954626 | 0.86 | PPARG (1.00) | PPARGCNR2CNR1TRPV1SLC6A3 | |
| Cannabigerol SCHEMBL14764730 | 0.86 | PPARG (1.00) | PPARGCNR2CNR1TRPV1SLC6A3 | |
| SCHEMBL23522965 | 0.85 | PPARG (0.97) | PPARGCNR2CNR1TRPV1SLC6A3 | |
| SCHEMBL23522969 | 0.85 | PPARG (0.97) | PPARGCNR2CNR1TRPV1SLC6A3 | |
| SCHEMBL23523042 | 0.85 | PPARG (0.97) | PPARGCNR2CNR1TRPV1SLC6A3 | |
| SCHEMBL23523554 | 0.85 | PPARG (0.97) | PPARGCNR2CNR1TRPV1SLC6A3 | |
| SCHEMBL23523493 | 0.85 | PPARG (0.97) | PPARGCNR2CNR1TRPV1SLC6A3 | |
| SCHEMBL23523451 | 0.85 | PPARG (0.97) | PPARGCNR2CNR1TRPV1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023198800-A1 | NEW COMPOSITIONS COMBINING AT LEAST ONE INORGANIC SOLAR FILTER, AND USE THEREOF | FRANCE COSMEPHYL-LAB (FR) | 2023-10-19 | — | — | WO | disclosed |
| US-20230284578-A1 | EXTRACTS OF CBD AND THC | NEXUS AGRISCIENCE, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230150927-A1 | CANNABIGEROL DERIVATIVES AND USE THEREOF AS CANNABINOID RECEPTOR MODULATORS | JGB COLLATERAL LLC | 2023-05-18 | — | — | US | disclosed |
| US-20220186063-A1 | BEVERAGE STRAW COATED WITH AN ACTIVE COMPOUND AND METHOD OF MANUFACTURING | UPSDELL MARK (CA) | 2022-06-16 | — | — | US | disclosed |
| WO-2022013227-A1 | NOVEL COMPOSITIONS COMBINING HEMP DERIVATIVES AND AT LEAST ONE PEPTIDE AND USE THEREOF | FRANCE COSMEPHYL-LAB (FR) | 2022-01-20 | — | — | WO | disclosed |
| WO-2021146687-A1 | A CANNABOSIDE COMPOSITION AND METHOD TO PRODUCE | CANNABIS GLOBAL, INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021119536-A1 | CANNABINOID ENRICHED COMPOSITION AND METHOD OF USING | CANNABIS GLOBAL, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2020014776-A1 | CANNABINOID ORAL DISPERSIBLE FILM STRIP | RAPID DOSE THERAPEUTICS CORP. (CA) | 2020-01-23 | — | — | WO | disclosed |
| WO-2019178360-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | POVIVA TEA, LLC (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2017100369-A1 | PRINTABLE CANNABINOID AND TERPENE COMPOSITIONS | Ebbu, LLC (US) | 2017-06-15 | — | — | WO | disclosed |
| US-9084771-B2 | Methods and compositions for treating cancer | SUTTER WEST BAY HOSPITALS (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140065243-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SUTTER WEST BAY HOSPITALS | 2014-03-06 | — | — | US | disclosed |
| US-20100204312-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2008144475-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140065243-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CNR2, CNR1, JUP | PPARG 124/4885CNR2 1/4885CNR1 2/4885 |
| US-20100204312-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CNR2, CNR1, JUP | PPARG 124/4885CNR2 1/4885CNR1 2/4885 |
| US-20230150927-A1 | CANNABIGEROL DERIVATIVES AND USE THEREOF AS CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | PPARG 77/4885CNR2 2/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.